Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ironwood Pharmaceuti (IRWD)

Ironwood Pharmaceuti (IRWD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,806,993
  • Shares Outstanding, K 153,395
  • Annual Sales, $ 413,750 K
  • Annual Income, $ 528,450 K
  • 60-Month Beta 0.99
  • Price/Sales 4.35
  • Price/Cash Flow 9.83
  • Price/Book 3.04
Trade IRWD with:

Options Overview Details

View History
  • Implied Volatility 55.43% ( +2.68%)
  • Historical Volatility 27.44%
  • IV Percentile 67%
  • IV Rank 30.34%
  • IV High 136.42% on 10/19/22
  • IV Low 20.16% on 03/16/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 54
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 1,736
  • Open Int (30-Day) 1,599

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 0.30
  • Number of Estimates 3
  • High Estimate 0.32
  • Low Estimate 0.29
  • Prior Year 0.27
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.88 +8.39%
on 11/03/22
11.91 -0.99%
on 11/28/22
+0.68 (+6.14%)
since 10/28/22
3-Month
9.73 +21.20%
on 10/10/22
11.91 -0.99%
on 11/28/22
+0.90 (+8.29%)
since 08/29/22
52-Week
9.73 +21.20%
on 10/10/22
12.95 -8.94%
on 03/30/22
+0.63 (+5.67%)
since 11/26/21

Most Recent Stories

More News
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the Piper Sandler 34 th Annual Healthcare Conference on Tuesday, November 29, 2022 at 4:30 p.m. ET at the Lotte New...

IRWD : 11.78 (+0.21%)
Ironwood's (IRWD) Q3 Earnings Beat, Linzess Volume Grows

Ironwood (IRWD) beat earnings estimates in the third quarter. Sales, though missing estimates, rose year over year. Stock up.

AZN : 66.40 (+0.29%)
IRWD : 11.78 (+0.21%)
NBIX : 122.39 (+0.60%)
ABBV : 158.62 (+0.12%)
Ironwood Pharmaceuticals (IRWD) Beats Q3 Earnings Estimates

Ironwood (IRWD) delivered earnings and revenue surprises of 3.70% and 2.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

IRWD : 11.78 (+0.21%)
FNCH : 0.8703 (+2.39%)
Ironwood: Q3 Earnings Snapshot

Ironwood: Q3 Earnings Snapshot

IRWD : 11.78 (+0.21%)
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2022 results and recent business performance.

IRWD : 11.78 (+0.21%)
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 3, 2022. Individuals...

IRWD : 11.78 (+0.21%)
Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds

Ironwood (IRWD) reports positive top-line data from a late-stage study evaluating Linzess (linaclotide) for functional constipation in pediatric patients aged six to 17 years.

IRWD : 11.78 (+0.21%)
ABBV : 158.62 (+0.12%)
CPRX : 16.63 (+0.85%)
SLNO : 1.0300 (-0.96%)
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced positive topline data from a Phase III clinical trial evaluating LINZESS (linaclotide) 72 mcg in pediatric patients aged 6-17 with functional...

IRWD : 11.78 (+0.21%)
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Thursday, September 8, 2022 at 8:00 a.m. ET at the Encore Boston Harbor...

IRWD : 11.78 (+0.21%)
Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance

Ironwood (IRWD) miss earnings and revenue estimates in the second quarter. Stock declines.

AZN : 66.40 (+0.29%)
IRWD : 11.78 (+0.21%)
ABBV : 158.62 (+0.12%)
IONS : 39.87 (-1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic...

See More

Key Turning Points

3rd Resistance Point 12.14
2nd Resistance Point 12.03
1st Resistance Point 11.90
Last Price 11.78
1st Support Level 11.66
2nd Support Level 11.55
3rd Support Level 11.42

See More

52-Week High 12.95
Last Price 11.78
Fibonacci 61.8% 11.72
Fibonacci 50% 11.34
Fibonacci 38.2% 10.96
52-Week Low 9.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar